Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed diagnosis of one of the following:

- Non-Hodgkin's lymphoma

- Primary or metastatic solid tumor located, by radiography, in at least one of
the following sites:

- Liver

- Soft tissue

- Pelvis

- Other site that is suitable for delayed contrast-enhanced MRI (e.g.,
peripheral lung field)

- Relapsed or refractory (including unresectable) disease

- Patients with solid tumors must have failed all curative chemotherapeutic
regimens

- Patients with non-Hodgkin's lymphoma must be refractory to at least 2 standard
chemotherapeutic regimens and rituximab

- Not amenable to available conventional therapies AND no standard therapy exists

- Measurable disease

- No prior or concurrent CNS metastases (brain or leptomeningeal)

- No primary intracranial tumor by MRI or CT scan

- No histologically confirmed squamous cell carcinoma of the lung

PATIENT CHARACTERISTICS:

Age

- 18 and over

Performance status

- ECOG 0-2

Life expectancy

- Not specified

Hematopoietic

- WBC ≥ 3,500/mm^3

- Absolute neutrophil count ≥ 1,500/mm^3

- Hemoglobin ≥ 9.0 g/dL

- Platelet count ≥ 100,000/mm^3

- No severe or uncontrolled hematologic condition

Hepatic

- Bilirubin ≤1.5 times upper limit of normal (ULN)

- AST and ALT ≤ 2.5 times ULN

- PT and PTT normal

- INR normal

- Hepatitis B surface antigen negative

- Hepatitis C antibody negative

Renal

- Creatinine ≤ ULN

- Urine protein/creatinine ratio ≤ 1

- No severe or uncontrolled renal condition

Cardiovascular

- No clinically significant acute electrocardiographic abnormalities

- LVEF normal by echocardiogram or MUGA within the past 12 months if there was prior
exposure to anthracyclines

- No untreated or uncontrolled hypertension

- No blood pressure > 150/100 mm Hg (despite treatment)

- No isolated systolic hypertension (i.e., systolic blood pressure > 180 mm Hg on at
least 2 determinations [on separate days] within the past 3 months)

- No New York Heart Association class II - IV heart disease

- No active coronary artery disease requiring acute medical management

- No angina requiring acute medical management

- No congestive heart failure requiring acute medical management

- No ventricular arrhythmia requiring acute medical management

- No stroke or transient ischemic event within the past 6 months

- No prior or concurrent peripheral vascular disease

- No angiographically or ultrasonographically documented arterial or venous
occlusive event

- No symptomatic claudication

- No symptomatic orthostatic hypotension

- No other severe or uncontrolled cardiovascular condition

Pulmonary

- No severe or uncontrolled pulmonary condition

- No pulmonary embolism within the past 6 months

Immunologic

- HIV negative

- No severe or uncontrolled immunologic condition

- No active current infection requiring antibiotics

- No prior hypersensitivity reaction to any recombinant proteins, including VEGF Trap

Other

- No severe or uncontrolled gastrointestinal or musculoskeletal condition

- No psychiatric condition or adverse social circumstance that would preclude study
participation

- No other condition that would preclude study participation

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective double-barrier contraception during and for 3
months after study treatment

PRIOR CONCURRENT THERAPY:

Biologic therapy

- See Disease Characteristics

- No prior participation in a VEGF Trap, interleukin-1 Trap, or interleukin-4/13 Trap
clinical trial

- At least 3 weeks since prior immunotherapy and recovered

- No concurrent epoetin alfa, filgrastim (G-CSF), or sargramostim (GM-CSF)

Chemotherapy

- See Disease Characteristics

- At least 3 weeks since prior chemotherapy and recovered

Endocrine therapy

- No concurrent adrenal corticosteroids except low-dose replacement therapy

- No concurrent systemic hormonal contraceptive agents

Radiotherapy

- At least 3 weeks since prior radiotherapy and recovered

Surgery

- At least 3 weeks since prior major or laparoscopic surgery and recovered

- More than 6 months since prior surgical procedure for correction or prophylaxis of
peripheral vascular insufficiency or cerebral ischemic events

Other

- More than 30 days since prior investigational drugs

- No concurrent anticoagulant or antiplatelet drugs (e.g., warfarin, heparin, or
aspirin) other than low-dose (1 mg) warfarin for maintaining patency of venous access
devices

- No concurrent non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2
(COX-2) inhibitors

- No other concurrent anticancer investigational agents

- No other concurrent anticancer therapy